# To Evaluate Safety and Efficacy of KX-826 in Chinese Female Subjects With Androgenetic Alopecia

> **NCT06409650** · PHASE2 · COMPLETED · sponsor: **Suzhou Koshine Biomedica, Inc.** · enrollment: 160 (actual)

## Conditions studied

- Alopecia

## Interventions

- **DRUG:** KX-826 dosed at 2.5mg
- **DRUG:** KX-826 dosed at 2.5mg
- **DRUG:** KX-826 dosed at 5 mg
- **DRUG:** KX-826 dosed at 5 mg
- **DRUG:** Matching placebo to KX-826
- **DRUG:** Matching placebo to KX-826

## Key facts

- **NCT ID:** NCT06409650
- **Lead sponsor:** Suzhou Koshine Biomedica, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-09
- **Primary completion:** 2022-11-10
- **Final completion:** 2023-12-07
- **Target enrollment:** 160 (ACTUAL)
- **Last updated:** 2024-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06409650

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06409650, "To Evaluate Safety and Efficacy of KX-826 in Chinese Female Subjects With Androgenetic Alopecia". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06409650. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*